Leon Rompay - Mithra Pharmaceuticals Chief Officer
| MITPFDelisted Stock | USD 6.75 0.00 0.00% |
Insider
Leon Rompay is Chief Officer of Mithra Pharmaceuticals SA
| Phone | 32 4 349 28 22 |
| Web | https://www.mithra.com |
Mithra Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1135) % which means that it has lost $0.1135 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.3893) %, meaning that it generated substantial loss on money invested by shareholders. Mithra Pharmaceuticals' management efficiency ratios could be used to measure how well Mithra Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Mithra Pharmaceuticals SA has accumulated 125.24 M in total debt with debt to equity ratio (D/E) of 9.62, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mithra Pharmaceuticals has a current ratio of 0.78, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Mithra Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Mithra Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mithra Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mithra to invest in growth at high rates of return. When we think about Mithra Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Lige, Belgium. Mithra Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 300 people. Mithra Pharmaceuticals SA [MITPF] is a Pink Sheet which is traded between brokers as part of OTC trading. Management Performance
| Return On Equity | -1.39 | |||
| Return On Asset | -0.11 |
Mithra Pharmaceuticals Leadership Team
Elected by the shareholders, the Mithra Pharmaceuticals' board of directors comprises two types of representatives: Mithra Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mithra. The board's role is to monitor Mithra Pharmaceuticals' management team and ensure that shareholders' interests are well served. Mithra Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mithra Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leon Rompay, Chief Officer | ||
| Cedric Darcis, Chief Officer | ||
| Graham Dixon, Chief Officer | ||
| Fanny Storms, Compliance Officer | ||
| Christophe Marechal, Chief Officer | ||
| Laurence Schyns, Chief Officer | ||
| Maud Vanderthommen, Group Mang | ||
| JeanManuel Fontaine, Chief Officer | ||
| Benoit Mathieu, Group Mang | ||
| Pr MD, Pres Director |
Mithra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Mithra Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.39 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (3.60) % | |||
| Current Valuation | 425.3 M | |||
| Shares Outstanding | 56.31 M | |||
| Shares Owned By Insiders | 32.32 % | |||
| Shares Owned By Institutions | 15.87 % | |||
| Price To Book | 9.76 X | |||
| Price To Sales | 17.08 X | |||
| Revenue | 22.67 M |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Mithra Pink Sheet
If you are still planning to invest in Mithra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mithra Pharmaceuticals' history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |